ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE
Noha A. El-Bassiouny, Amira B. Kassem, M. Abd-Alhaseeb, M. Tolba
{"title":"ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE","authors":"Noha A. El-Bassiouny, Amira B. Kassem, M. Abd-Alhaseeb, M. Tolba","doi":"10.21608/bfsa.2022.271642","DOIUrl":null,"url":null,"abstract":"Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes severe acute respiratory syndrome (SARS). It was discovered in December 2019 in Wuhan, China., which subsequently led to a nationwide outbreak. The World Health Organization included the AstraZeneca and Sinopharm vaccines for the WHO Emergency Use List on February 16 and May 7, 2021, respectively. Egyptians have gotten 2,623,200 doses of AstraZeneca's COVID-19 vaccination plus 500,000 doses of Sinopharm vaccine. The trial would test the vaccinations' short-term side effects on Egyptian people aged 18 and older. Result(s): Most symptoms decreased significantly after the second dose when compared to symptoms seen at the first dose .In addition, both doses reduced symptoms significantly compared to the first dose.Interestingly, the desire to sleep appears to significantly increase the side effects again after both doses when compared to the second dose alone. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Conclusion(s): Mild to moderate side effects are to be expected after the vaccination process because the body's immunomodulatory instructions can lead to negative symptoms. Symptoms include injection site soreness, fever, tiredness, headache, muscle aches, chills, and diarrhoea.. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Training and continuing education are needed to improve universal vaccine acceptance and reduce frequency. Copyright © 2022 Assiut University. All rights reserved.","PeriodicalId":345040,"journal":{"name":"Bulletin of Pharmaceutical Sciences. Assiut","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Pharmaceutical Sciences. Assiut","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/bfsa.2022.271642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes severe acute respiratory syndrome (SARS). It was discovered in December 2019 in Wuhan, China., which subsequently led to a nationwide outbreak. The World Health Organization included the AstraZeneca and Sinopharm vaccines for the WHO Emergency Use List on February 16 and May 7, 2021, respectively. Egyptians have gotten 2,623,200 doses of AstraZeneca's COVID-19 vaccination plus 500,000 doses of Sinopharm vaccine. The trial would test the vaccinations' short-term side effects on Egyptian people aged 18 and older. Result(s): Most symptoms decreased significantly after the second dose when compared to symptoms seen at the first dose .In addition, both doses reduced symptoms significantly compared to the first dose.Interestingly, the desire to sleep appears to significantly increase the side effects again after both doses when compared to the second dose alone. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Conclusion(s): Mild to moderate side effects are to be expected after the vaccination process because the body's immunomodulatory instructions can lead to negative symptoms. Symptoms include injection site soreness, fever, tiredness, headache, muscle aches, chills, and diarrhoea.. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Training and continuing education are needed to improve universal vaccine acceptance and reduce frequency. Copyright © 2022 Assiut University. All rights reserved.
阿斯利康和国药控股的疫苗在第一次和第二次注射时的不良反应。横断面研究埃及的经验
背景:严重急性呼吸综合征冠状病毒2型(SARS- cov -2)是引起严重急性呼吸综合征(SARS)的新型冠状病毒。它于2019年12月在中国武汉被发现。随后导致了全国范围的疫情爆发。世界卫生组织分别于2021年2月16日和5月7日将阿斯利康和国药控股的疫苗列入世界卫生组织紧急使用清单。埃及人已经接种了262.32万剂阿斯利康新冠疫苗和50万剂国药集团疫苗。该试验将测试疫苗对18岁及以上的埃及人的短期副作用。结果:与第一次给药时的症状相比,大多数症状在第二次给药后显著减轻。此外,与第一次给药相比,两次给药都显著减轻了症状。有趣的是,与单独服用第二剂相比,两种剂量后的睡眠欲望似乎再次显著增加了副作用。大多数或几乎所有参与者(96.5%)在接种疫苗后没有感染。结论:由于机体的免疫调节指令可导致阴性症状,因此疫苗接种过程后可能出现轻度至中度的副作用。症状包括注射部位疼痛、发烧、疲倦、头痛、肌肉疼痛、寒战和腹泻。大多数或几乎所有参与者(96.5%)在接种疫苗后没有感染。需要培训和继续教育,以提高普遍接受疫苗和减少频率。版权所有©2022阿西尤特大学。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。